Scientists have built upon BTE technology to develop new and improved recombinant and synthetic DNA versions of therapeutic antibodies that target CA9, called Persistent Multivalent T Cell Engager (CA9-PMTE), that shows promise in pre-clinical models as a potent, long-lasting treatment against ccRCC.
Scientists develop novel antibody treatment for kidney cancer
- Post author:
- Post published:June 5, 2024
- Post category:News Feed
- Post comments:0 Comments